GlassScriptPhysician profile
Paul R Sweeney
NPI 1174693345
$8,560.99
in general payments reported to CMS, 2019-2025
32 companies · $36.40 in 2025
The $36.40 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,766 · 2020: $1,656 · 2021: $2,267 · 2022: $1,749 · 2024: $87.13 · 2025: $36.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,400.50 | 2019-2022 | |
| Abbvie INC. | $1,280.38 | 2019-2024 | |
| Amgen INC. | $1,176.62 | 2019-2025 | Otezla, Enbrel |
| Glaxosmithkline, LLC. | $499.28 | 2019-2022 | |
| Janssen Biotech, INC. | $471.15 | 2019-2024 | Tremfya |
| Mallinckrodt Hospital Products INC. | $448.73 | 2020-2022 | |
| Ucb, INC. | $440.27 | 2019-2022 | |
| Lilly USA, LLC | $361.72 | 2019-2022 | |
| Pfizer INC. | $358.00 | 2019-2022 | |
| Radius Health, INC. | $355.11 | 2019-2022 | |
| Sobi, INC | $274.77 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $257.24 | 2019-2021 | |
| Horizon Therapeutics Plc | $191.13 | 2020-2021 | |
| Depuy Synthes Sales INC. | $156.18 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $154.00 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $118.52 | 2021-2022 | |
| Genzyme Corporation | $89.29 | 2019-2021 | |
| Genentech USA, INC. | $78.61 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $72.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $69.66 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $50.75 | 2019-2021 | |
| Fidia Pharma USA INC. | $46.63 | 2021 | |
| Celgene Corporation | $43.89 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.55 | 2019 | |
| Merck Sharp & Dohme LLC | $23.54 | 2019 | |
| Zyla Life Sciences, INC. | $22.68 | 2019 | |
| Pacira Therapeutics, INC. | $19.38 | 2020 | |
| Eyevance Pharmaceuticals LLC | $17.46 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.31 | 2019 | |
| Sebela Pharmaceuticals INC. | $15.03 | 2019 | |
| Bioventus LLC | $14.35 | 2019 | |
| Medexus Pharma, INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.